What is Palisade Bio?
Palisade Bio is a late-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic gastrointestinal issues, particularly those arising from post-operative digestive enzyme damage. The company's lead asset, LB1148, is a protease inhibitor currently in Phase 3-ready development. This therapeutic candidate has shown promise in clinical trials for its potential to mitigate abdominal adhesions and facilitate the restoration of bowel function post-surgery. Previous Phase 2 studies have highlighted LB1148's favorable safety and tolerability profile, alongside statistically significant improvements in the return of bowel function and reductions in intensive care unit and overall hospital stays compared to placebo.
How much funding has Palisade Bio raised?
Palisade Bio has raised a total of $4.4M across 2 funding rounds:
Stock/Share Issuance
$3.9M
Private Equity
$500K
Stock/Share Issuance (2025): $3.9M, investors not publicly disclosed
Private Equity (2026): $500K led by Crohn's & Colitis Foundation
Key Investors in Palisade Bio
Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is a non-profit organization dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life for affected individuals. Their investment suggests a focus on therapies that could benefit patients with inflammatory bowel conditions.
What's next for Palisade Bio?
The substantial enterprise-level backing and recent strategic investment signal a pivotal growth phase for Palisade Bio. This financing is expected to accelerate the progression of LB1148 through its Phase 3 trials and support broader operational scaling. The company's focus on addressing unmet needs in post-operative gastrointestinal care, coupled with promising clinical data, positions it for significant market impact. Future strategic capital allocation will likely concentrate on clinical development, regulatory submissions, and potential commercialization efforts, underscoring a commitment to bringing this vital therapy to patients.
See full Palisade Bio company page
